Eyepoint Pharmaceuticals (NASDAQ:EYPT) issued its earnings results on Thursday. The company reported ($0.15) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.14) by ($0.01), Fidelity Earnings reports. Eyepoint Pharmaceuticals had a negative return on equity of 165.24% and a negative net margin of 621.04%. The company had revenue of $2.51 million for the quarter, compared to the consensus estimate of $4.81 million.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.
Shares of NASDAQ:EYPT traded down $0.21 during trading on Friday, hitting $1.45. 1,551,100 shares of the company’s stock traded hands, compared to its average volume of 422,976. The company has a market cap of $247.67 million, a price-to-earnings ratio of -2.50 and a beta of 1.79. Eyepoint Pharmaceuticals has a 52 week low of $1.19 and a 52 week high of $2.82. The company has a 50-day moving average price of $2.12 and a 200-day moving average price of $1.71. The company has a current ratio of 5.46, a quick ratio of 5.31 and a debt-to-equity ratio of 1.75.
EYPT has been the topic of a number of recent analyst reports. Zacks Investment Research upgraded Eyepoint Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Friday. Guggenheim initiated coverage on Eyepoint Pharmaceuticals in a report on Thursday, September 12th. They set a “buy” rating and a $4.00 target price on the stock. ValuEngine cut Eyepoint Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Friday. B. Riley cut their price objective on Eyepoint Pharmaceuticals from $5.75 to $4.00 and set a “buy” rating on the stock in a report on Tuesday, September 24th. Finally, Laidlaw initiated coverage on Eyepoint Pharmaceuticals in a report on Monday, November 4th. They set a “buy” rating and a $5.00 price objective on the stock. Two analysts have rated the stock with a hold rating and four have assigned a buy rating to the stock. The stock currently has an average rating of “Buy” and a consensus target price of $3.95.
Eyepoint Pharmaceuticals Company Profile
EyePoint Pharmaceuticals, Inc, a specialty biopharmaceutical company, develops and commercializes ophthalmic products for the treatment of eye diseases in the United States and Europe. It provides ILUVIEN for the treatment of diabetic macular edema; YUTIQ, a non-erodible fluocinolone acetonide insert for the treatment of non-infectious posterior uveitis (NIPU) that is in the Phase III clinical trials; and Retisert (fluocinolone acetonide intravitreal implant), a sustained-release implant for the treatment of posterior segment uveitis.
Featured Story: Basic Economics